AEZ Share Price

Open 4.32 Change Price %
High 4.32 1 Day 0.01 0.24
Low 4.15 1 Week -0.23 -5.25
Close 4.15 1 Month 0.72 20.99
Volume 6841 1 Year -0.14 -3.26
52 Week High 7.32
52 Week Low 3.10
AEZ Important Levels
Resistance 2 4.31
Resistance 1 4.24
Pivot 4.21
Support 1 4.06
Support 2 3.99
TSE Canada Most Active Stocks
KAT 0.39 -33.90%
KAT 0.39 -33.90%
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
YRI 3.75 -4.09%
SC 60.83 -0.44%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
GLG 0.37 15.62%
CUM 0.90 13.92%
CUM 0.90 13.92%
CCM 0.10 11.11%
More..
TSE Canada Top Losers Stocks
KAT 0.39 -33.90%
KAT 0.39 -33.90%
GBV 0.46 -24.59%
HE 0.04 -20.00%
HE 0.04 -20.00%
RN 0.16 -20.00%
RN 0.16 -20.00%
MM 0.06 -14.29%
MM 0.06 -14.29%
BAA 0.18 -10.00%
More..

AEterna Zentaris, Inc. (TSE: AEZ)

AEZ Technical Analysis 3
As on 22nd Feb 2017 AEZ Share Price closed @ 4.15 and we RECOMMEND Sell for LONG-TERM with Stoploss of 4.57 & Sell for SHORT-TERM with Stoploss of 4.22 we also expect STOCK to react on Following IMPORTANT LEVELS.
AEZ Target for February
1st Target up-side 5.18
2nd Target up-side 5.89
3rd Target up-side 6.61
1st Target down-side 3.14
2nd Target down-side 2.43
3rd Target down-side 1.71
AEZ Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.aezsinc.com
AEZ Address
AEZ
1405 du Parc-Technologique Boulevard
Quebec City, QC G1P 4P5
Canada
Phone: 418-652-8525
Fax: 418-948-9191
Interactive Technical Analysis Chart AEterna Zentaris, Inc. ( AEZ TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AEterna Zentaris, Inc.
AEZ Business Profile
Aeterna Zentaris Inc., a specialty biopharmaceutical company, develops and commercializes novel treatments in oncology and endocrinology worldwide. The company’s product pipeline includes MACRILEN, a product candidate for which the company has filed a New Drug Application to the FDA as an oral product used for evaluating adult growth hormone deficiency; and is also investigated in Phase 2A clinical trials to treat cancer-induced cachexia. Its product pipeline also comprises Zoptarelin doxorubicin, which has completed Phase 2 clinical trials to treat ovarian and endometrial cancer, and breast cancer; and Phase 1/2 clinical trials to treat bladder and prostate cancers. In addition, the company’s product candidates in clinical and preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate; PI3K/Erk inhibitors, including AEZS-129 and AEZS-136 for oncology; and disorazol Z product candidates, such as AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.